Results 201 to 210 of about 4,350,325 (326)
In-silico Identification of Novel Drug Target for Osteoarthritis using Network Biology Approaches
, 2022 Nityendra Shukla +4 more
openalex +1 more source
Genomics‐led approach to drug testing in models of undifferentiated pleomorphic sarcoma
Molecular Oncology, EarlyView.GA text Genomic data from undifferentiated pleomorphic sarcoma patients and preclinical models were used to inform a targeted drug screen. Selected compounds were tested in 2D and 3D cultures of UPS cell lines. A combination of trametinib and infigratinib was synergistic in the majority of UPS cell lines tested, which was further confirmed in an ex ...
Piotr J. Manasterski +19 more
wiley +1 more source
Bioinformatics analysis to explore biomarkers and mechanisms of action associated with endoplasmic reticulum stress and ferroptosis in Parkinson's disease. [PDF]
PLoS OneWang H +5 more
europepmc +1 more source
Molecular Oncology, EarlyView.This study identifies nuclear YB‐1 S102 phosphorylation as a marker associated with KRAS and FBXW7 mutations in colorectal cancer. Mutated KRAS correlates specifically with nuclear, not cytoplasmic, S102 YB‐1. These findings provide the first ex vivo evidence of this link in CRC and suggest future studies should assess the prognostic and therapeutic ...
Konstanze Lettau +9 more
wiley +1 more source
TNF biology, pathogenic mechanisms and emerging therapeutic strategies
Nature Reviews Rheumatology, 2016 G. Kalliolias, L. Ivashkiv
semanticscholar +1 more source
A nucleotide‐independent, pan‐RAS‐targeted DARPin elicits anti‐tumor activity in a multimodal manner
Molecular Oncology, EarlyView.We report a Designed Ankyrin Repeat Protein that binds and inhibits RAS proteins, which serve as central cell signaling hubs and are essential for the progression of many cancers. Its unique feature is that it does not discriminate between different RAS isoforms or mutations and is capable of binding to RAS in both its active (GTP‐bound) and inactive ...
Jonas N. Kapp +13 more
wiley +1 more source
Functional metabolomics: unlocking the role of small molecular metabolites. [PDF]
Front Mol BiosciChen H +8 more
europepmc +1 more source
Molecular Oncology, EarlyView.C–C chemokine receptor type 9 (CCR9) is an immune checkpoint in pancreatic ductal adenocarcinoma (PDAC). Novel anti‐CCR9 antibody SRB2 was evaluated in combination with cytotoxic chemotherapy in PDAC cells, patient‐derived organoids, patient‐derived xenografts, and humanized mouse models.
Hannah G. McDonald +18 more
wiley +1 more source